Published in Oncoimmunology on November 11, 2015
Amelioration of Inflammatory Cytokines Mix Stimulation: A Pretreatment of CD137 Signaling Study on VSMC. Mediators Inflamm (2017) 0.75
Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype. Sci Rep (2016) 0.75
CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth. Oncoimmunology (2016) 0.75
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev (2009) 2.34
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A (1989) 2.13
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol (1998) 2.11
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol (1999) 1.95
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med (2015) 1.87
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood (2009) 1.79
In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol (2002) 1.70
Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant (2003) 1.61
Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther (2003) 1.53
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol (2007) 1.52
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest (2003) 1.52
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol (2002) 1.45
Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med (1999) 1.37
CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J (2006) 1.34
CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol (2010) 1.29
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med (2013) 1.29
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol (1998) 1.24
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest (2007) 1.17
Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol (2009) 1.16
CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol (2008) 1.16
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood (2004) 1.13
CD137-mediated immunotherapy for allergic asthma. J Clin Invest (2006) 1.13
4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine (2006) 1.13
CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol (2008) 1.08
Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology (2004) 1.08
CD137 induces proliferation and endomitosis in monocytes. Blood (1999) 1.05
4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol (1999) 1.05
Induction of proliferation and monocytic differentiation of human CD34+ cells by CD137 ligand signaling. Stem Cells (2008) 1.04
CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol (2002) 1.04
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res (2014) 1.03
Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood (2009) 1.02
Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Natl Acad Sci U S A (2003) 0.98
Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol (2011) 0.97
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett (2005) 0.96
A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene (1993) 0.95
Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res (2012) 0.95
A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol (2009) 0.93
Characterisation of soluble murine CD137 and its association with systemic lupus. Mol Immunol (2008) 0.92
Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology (2012) 0.92
Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol (1999) 0.92
Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death. J Immunol (2010) 0.90
Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol (2006) 0.90
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep (2014) 0.90
Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase. J Immunol (2012) 0.90
Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia (2005) 0.89
CD137 ligand signaling induces human monocyte to dendritic cell differentiation. Eur J Immunol (2010) 0.89
Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease. Biol Blood Marrow Transplant (2009) 0.89
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res (2015) 0.88
CD137 ligand signaling enhances myelopoiesis during infections. Eur J Immunol (2013) 0.87
CD137 enhances monocyte-ICAM-1 interactions in an E-selectin-dependent manner under flow conditions. Mol Immunol (2010) 0.87
The pathophysiology of chronic graft-versus-host disease. Int J Hematol (2004) 0.87
SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res (2014) 0.87
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
A humanized anti--4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother (2001) 0.85
NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology (2015) 0.84
Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun (2003) 0.84
CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann N Y Acad Sci (2003) 0.84
Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells. PLoS One (2010) 0.83
Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J Neurosci (2012) 0.82
Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun (2013) 0.81
Costimulatory TNFR family members in control of viral infection: outstanding questions. Semin Immunol (2014) 0.80
4-1BB chimeric antigen receptors. Cancer J (2014) 0.80
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology (2014) 0.79
Role of endogenous 4-1BB in the development of systemic lupus erythematosus. Immunology (2007) 0.79
Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation. J Leukoc Biol (2015) 0.78
CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses. Oncoimmunology (2013) 0.78
CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells. Br J Haematol (2014) 0.76
Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice. Eur J Immunol (2015) 0.76